MTOR and diabetic kidney disease: reported that the insulin-regulated phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)/mammalian target of rapamycin (mTOR) signaling pathway was activated in db/db mice with the long-term administration of atorvastatin or rosuvastatin, which may increase insulin resistance, interfere with lipid metabolism, and lead to inflammation and fibrosis, ultimately exacerbating diabetic nephropathy progression (35).